Indocyanine green fluorescence imaging to visualize tenosynovial giant cell tumor during surgery.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center, single-arm study gives eligible TGCT patients an intravenous injection of indocyanine green 1–3 hours before surgery and uses a near-infrared camera to visualize fluorescent tissue during the operation. After standard resection under white light, the surgical bed will be systematically scanned and the surgeon will collect samples from fluorescence-positive areas and fluorescence-negative background tissue. All specimens will undergo blinded pathological review to determine true tumor presence. The study will report sensitivity, specificity, positive and negative predictive values and perform secondary analyses such as tumor-to-background ratios and microscopic boundary concordance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with Tenosynovial Giant Cell Tumor (TGCT), including both Localized-type (L-TGCT) and Diffuse-type (D-TGCT), via preoperative biopsy or typical imaging (MRI), and scheduled for surgical resection.
* Capable of understanding the study and voluntarily signing the written informed consent form.

Exclusion Criteria:

* Known severe history of allergy to Indocyanine Green (ICG) or iodine.
* Severe liver dysfunction.
* Women who are pregnant or lactating.

Where it's running

• Shanghai Sixth People's Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Qingcheng Yang, Prof.
• Email: tjyqc@163.com
• Phone: +86 21 6431 9181

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pimicotinib for Japanese people with tenosynovial giant cell tumor (J-MANEUVER)

  This trial will test whether pimicotinib is safe, reaches effective blood levels, and improves symptoms in Japanese participants with unresectable tenosynovial giant cell tumor.

  Recruiting at 4 sites Phase 2 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Chūōku and 3 other locations · NCT07499362

• Real-world experience with vimseltinib for tenosynovial giant cell tumor

  This registry will collect real-world information about how people with TGCT take vimseltinib and how it affects their symptoms and quality of life.

  Recruiting Deciphera Pharmaceuticals, LLC · Wilmington, North Carolina · NCT07075471

• Assessing the safety and tolerability of ABSK-021 in patients with advanced solid tumors

  This study is testing a new oral medication called ABSK-021 to see if it's safe and tolerable for people with advanced solid tumors, especially those with tenosynovial giant cell tumor, who haven't had success with other treatments.

  Recruiting at 3 sites Phase 1 Abbisko Therapeutics Co, Ltd · Beverly Hills, California and 16 other locations · NCT04192344

• Evaluating treatments for non-rhabdomyosarcoma soft tissue sarcoma in young patients

  This study is testing a combination of chemotherapy and radiation to see if it helps young patients with non-rhabdomyosarcoma soft tissue sarcoma live longer without their cancer coming back.

  Recruiting at 7 sites Phase 1/2 St. Jude Children's Research Hospital · Atlanta, Georgia and 6 other locations · NCT06239272

• TRACP-5b test to help diagnose and monitor giant cell tumor of bone

  This study tests whether a blood marker, TRACP-5b, can help diagnose and track giant cell tumor of bone in adults.

  Recruiting St. Anne's University Hospital Brno, Czech Republic · Brno · NCT07609277

• Indocyanine green fluorescence to find leftover giant cell tumor tissue during surgery

  We will try a dye called indocyanine green with near-infrared imaging during surgery to help surgeons spot any remaining giant cell tumor tissue in people having surgery for GCTB.

  Recruiting Phase 4 Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Shanghai · NCT07315828

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.